Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.2
(-3.51%)
SEK 2.2
(-3.51%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3 Million SEK | -93.78% |
| 2022 | 48.29 Million SEK | 1647.85% |
| 2021 | 2.76 Million SEK | -17.47% |
| 2020 | 3.34 Million SEK | -20.1% |
| 2019 | 4.19 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 8.06 Million SEK | 7.32% |
| 2024 Q2 | 7.96 Million SEK | 1.8% |
| 2023 Q4 | 3 Million SEK | -38.13% |
| 2023 Q2 | 5.25 Million SEK | -88.92% |
| 2023 FY | 3 Million SEK | -93.78% |
| 2023 Q1 | 47.39 Million SEK | -1.87% |
| 2023 Q3 | 4.85 Million SEK | -7.52% |
| 2022 Q1 | 4.46 Million SEK | 61.64% |
| 2022 FY | 48.29 Million SEK | 1647.85% |
| 2022 Q2 | 48.24 Million SEK | 980.32% |
| 2022 Q3 | 49.27 Million SEK | 2.13% |
| 2022 Q4 | 48.29 Million SEK | -1.99% |
| 2021 FY | 2.76 Million SEK | -17.47% |
| 2021 Q1 | 4.22 Million SEK | 26.11% |
| 2021 Q3 | 3.69 Million SEK | -11.59% |
| 2021 Q4 | 2.76 Million SEK | -25.18% |
| 2021 Q2 | 4.17 Million SEK | -1.07% |
| 2020 Q1 | 4.45 Million SEK | 6.24% |
| 2020 Q2 | 4.21 Million SEK | -5.23% |
| 2020 FY | 3.34 Million SEK | -20.1% |
| 2020 Q4 | 3.34 Million SEK | -21.17% |
| 2020 Q3 | 4.24 Million SEK | 0.66% |
| 2019 FY | 4.19 Million SEK | 0.0% |
| 2019 Q4 | 4.19 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.794% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.794% |
| Arcoma AB | 1.92 Million SEK | -55.89% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 92.899% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.829% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 94.794% |
| CellaVision AB (publ) | 28.66 Million SEK | 89.52% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -1247.085% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -71.363% |
| Duearity AB (publ) | 2.94 Million SEK | -2.177% |
| Dignitana AB (publ) | 6.07 Million SEK | 50.568% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -30.609% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.923% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 52.715% |
| Iconovo AB (publ) | 4.9 Million SEK | 38.78% |
| Integrum AB (publ) | 4.84 Million SEK | 37.992% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -1358.083% |
| Mentice AB (publ) | 2.14 Million SEK | -40.112% |
| OssDsign AB (publ) | 214 Thousand SEK | -1303.738% |
| Paxman AB (publ) | 2.53 Million SEK | -18.641% |
| Promimic AB (publ) | - SEK | -Infinity% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 28.117% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 84.357% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -196.838% |
| Senzime AB (publ) | 8.57 Million SEK | 64.98% |
| SpectraCure AB (publ) | 4.39 Million SEK | 31.681% |
| Stille AB | 38.06 Million SEK | 92.108% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.84% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 85.809% |